Dec 14, 2023
We are thrilled to share that MarWell Bio Inc. has completed the exhilarating 8-week National Science Foundation (NSF) I-Corps All SBIR Program! This experience has been truly transformative, shaping our vision and approach in incredible ways.
A sincere thank you goes out to our exceptional team for their unwavering dedication and hard work over the past 8 weeks, culminating in the successful completion of this program and delivering truly outstanding results. Our heartfelt gratitude to the NSF for this incredible opportunity that has opened new doors for MarWell Bio Inc. Immense thanks to the dedicated NSF I-Corps teaching team whose unwavering support fueled our journey through this intensive program. The future looks incredibly bright for MarWell Bio Inc., and we are filled with enthusiasm about the opportunities that await us in the future!
MarWell Bio Inc. was awarded NSF I-Corps Grant and Successfully Completed the Cohort!
August 30, 2023
We are thrilled to announce that our pioneering Generative AI Antibody Drug Design Company MarWell Bio Inc. has been awarded Phase I National Science Foundation (NSF) SBIR funding! This funding will be instrumental in advancing our pioneering and cutting-edge Generative AI-driven Antibody Drug Design Efforts.
At MarWell Bio Inc. we are determined to reshape the landscape of healthcare, improving the lives of countless patients across the globe. Our groundbreaking Generative AI-driven approach holds the promise of innovative treatments and, ultimately, the cure for previously untreatable conditions.
The National Science Foundation (NSF) has always played an instrumental role in shaping the future of innovation by providing crucial support and guidance for impactful breakthroughs with high social and economic impact. We're truly grateful for this opportunity and excited about the possibilities ahead!
Santa Clara, California
Aug 30, 2023
We are thrilled to announce that our pioneering Generative AI Antibody Drug design company MarWell Bio Inc., has been selected and accepted into the NVIDIA Inception Accelerator Program!
This milestone wouldn't have been possible without our incredibly dedicated and innovative team. The NVIDIA Inception program is renowned for supporting startups that are at the forefront of AI and Deep Learning innovation. Being part of this elite community opens up a world of possibilities for MarWell Bio Inc.
As the world's first Generative AI Antibody Drug Design company we're excited to take MarWell Bio Inc.’s capabilities to the next level and contribute to the advancement of drug development using our breakthrough GenerativeAI. Together, we'll continue to make a positive impact on healthcare and improve the lives of countless individuals around the world.
MarWell Bio has been selected as one of the Top 3 Finalists for the ONO Pharmaceutical LabCentral Golden Ticket 2023 Competition!
June 22, 2023
We are thrilled to announce that our leading Generative AI Antibody Drug Design company MarWell Bio Inc. has been selected as one of the Top 3 Finalists for the prestigious ONO Pharmaceutical LabCentral Golden Ticket 2023 competition, amongst many other applicants!
It is with immense joy and pride that we share this incredible opportunity to present as the world's first Generative AI Antibody Drug Design company alongside two other outstanding national finalists!
Being chosen as one of the top 3 companies is a true honor, and we are humbled to share the stage with fellow trailblazers who are shaping the future of the Pharma industry. This remarkable achievement not only demonstrates our team’s unwavering commitment and exceptional expertise but also underscores their steadfast dedication to delivering improved therapies to patients who require them the most!
MarWell Bio Inc. presented its breakthrough Generative AI Antibody Drug Design technologies as one of the Top Finalists at the prestigious annual WIB-Greater Boston pitch event at Bio2023 on June 7, 2023!
June 7, 2023
We are thrilled to share that our pioneering Generative AI Drug Design company MarWell Bio Inc., presented as a Top Finalist at the prestigious Annual WIB-Greater Boston at BIO2023 in Boston today. It is a tremendous honor to be recognized among the industry's brightest minds and showcase our groundbreaking work in the field of drug design and discovery.
Since our inception over three years ago, MarWell Bio Inc. has pioneered the development of proprietary Generative AI technologies for Antibody Drug Design. We take great pride in the significant milestones we have achieved on our journey to commercialize these groundbreaking technologies, poised to completely revolutionize the field. With an unwavering commitment, our ultimate mission is to deliver life-saving therapeutics to patients around the globe, empowering them to lead healthier and more fulfilling lives.
MarWell Bio Inc. is selected as a 2023 American Cancer Society (ACS) BrightEdge Golden Ticket Finalist!
April 13, 2023
We are thrilled to share that our pioneering Generative AI Antibody Drug Design company MarWell Bio Inc. is selected as a 2023 American Cancer Society (ACS) BrightEdge Golden Ticket Finalist! We successfully developed the world's first Generative-AI platform for rapid, high-precision, and low-cost antibody drug design in 2020. After 3 years of tireless work and achieving significant technology development and validation milestones we are emerging out of stealth mode to change the lives of millions of patients around the world through our cutting-edge antibody drug design platform. We are very excited about the possibility of joining Bakar Labs' world-class laboratories and accessing the American Cancer Society BrightEdge team of top-notch scientific and industry advisors!